Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI

Safety and efficacy of adjunctive antiplatelet therapy prior to primary percutaneous intervention (PCI) in patients with ST-Elevation Myocardial Infarction (STEMI)

Inclusion Criteria: * Persistent ST elevation ≥ 1mm (≥ 0.1mV) in two contiguous limb leads OR ≥ 2 mm (≥ 0.2mV) in two contiguous precordial leads, AND chest pain ≥ 20 minutes with onset within 6 hours of hospital presentation. Exclusion Criteria: * Cardiogenic shock (systolic blood pressure \< 90 mm Hg requiring vasopressor or hemodynamic support) * Uncontrolled hypertension defined as any measured systolic blood pressure (SBP) \> 180 mm Hg or diastolic blood pressure (DBP) ≥ 110 mm Hg after the time -- History or symptoms of a congenital or acquired bleeding disorder or vascular malformation. * Recent gastrointestinal bleeding within the last 30 days. * Known thrombocytopenia (platelet count \< 100,000/mm3). * Any treatment with a fibrinolytic agent within the last 7 days.